We use cookies for a better user experience. Read our Privacy Policy

I Agree

Sodium Phenylbutyrate Drugs Market

Sodium Phenylbutyrate Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 - 2030

Sodium Phenylbutyrate Drugs Market: Introduction

Sodium phenylbutyrate drugs are prescribed for adjunctive therapy in the chronic management of urea cycle disorders. They are primarily administered orally, in equally divided doses, with each meal or feeding. Divalproex (Depakote), haloperidol (Haldol), valproic acid (Depakene, Stavzor) may interact with sodium phenylbutyrate, if taken simultaneously. Buphenyl is a brand name of sodium phenylbutyrate, approved by the FDA.

Request a sample to get extensive insights into the Sodium Phenylbutyrate Drugs Market

 Key Drivers and Restraints of Global Sodium Phenylbutyrate Drugs Market

  • Urea cycle disorders (UCDs) are inborn errors of metabolism (IEMs) resulting from defects in any 1 of the six enzymes or 2 transporters involved in the hepatic removal of ammonia from the bloodstream by conversion to urea, which is excreted by the kidneys. UCDs include carbamoyl phosphate synthase (CPS) deficiency, ornithine transcarbamylase (OTC) deficiency, argininosuccinate synthetase deficiency (citrullinemia), argininosuccinate lyase deficiency (argininosuccinic aciduria), and arginase deficiency (argininemia). Overall incidence of UCD, globally, varies from 1:8000 to 1:44,000 births. An estimated cumulative incidence of UCDs in Europe is approximately 1 in 51,946. Sodium phenylbutyrate drugs are utilized for the treatment of urea cycle disorders. Thus, an increase in cases of UCDs fuel the market.
  • Increased research & development initiatives undertaken by research & academic institutes supported by pharmaceutical companies as well as governments are estimated to drive sodium phenylbutyrate drugs market
  • Side effects related to the intake of sodium phenylbutyrate drugs may hamper the market. Common side effects may include missed menstrual periods or changes in the regular cycle, loss of appetite, headache, nausea or vomiting, lower back, side, or stomach pain.

Oral Segment Witness Highest Growth

  • Based on route of administration, the global sodium phenylbutyrate drugs market can be divided into oral and nasogastric intubation
  • The oral segment accounted for a prominent share of the market in 2019. Sodium phenylbutyrate is available in tablet or powder form. Nasogastric intubation involves the insertion of a plastic tube through the nose, past the throat, and down into the stomach. Nasogastric tube (NGT) insertion is done through anesthetized procedure for critically ill patients who cannot swallow a tablet through oral intake.

Hospital Pharmacies to Dominate Global Sodium Phenylbutyrate Drugs Market

  • Based on distribution channel, the global sodium phenylbutyrate drugs market can be divided into: hospital pharmacies, online and retail pharmacies
  • In terms of revenue, the hospital pharmacies segment accounted for a notable share of the global market in 2019, followed by the retail pharmacies segment. Within a hospital, the hospital pharmacy dispenses inpatient medications. Hospital pharmacies usually stock a larger range of medications. Expansion of hospital pharmacies is attributed to offering quality medicines to patient by purchasing directly from drug manufacturers, thus preventing the issues of counterfeit medicines.
  • The online segment is estimated to expand at a significant CAGR during the forecast period. Increasing penetration of internet, worldwide, rising investments made by private companies, and an increase in the number of steps taken by government bodies are major factors propelling the segment

North America to Dominate Global Sodium Phenylbutyrate Drugs Market

  • In terms of region, the global sodium phenylbutyrate drugs market can be divided into: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
  • In terms of revenue, North America dominated the sodium phenylbutyrate drugs market. Increase in incidence of urea cycle disorders, rise in number of FDA approvals, and continuous merger & acquisition between companies contribute to the leading share held by the region. According to data published in NCBI in 2013, incidence of urea cycle disorders is at 1 in 35,000 live births in the U.S. or about 113 new patients per year.
  • The sodium phenylbutyrate drugs market in Asia Pacific is anticipated to be driven by an increase in the number of target patients, rise in healthcare expenditure, and investments by various companies in research & development activities in the region.

To understand how our report can bring difference to your business strategy, Ask for a brochure

Key Manufacturers Operating in Market

The global sodium phenylbutyrate drugs market was highly fragmented in 2019. Key manufacturers operating in the global market are:

  • Horizon Therapeutics USA, Inc.
  • Par Pharm
  • Sigmapharm Labs LLC
  • Alvogen
  • Bausch Health Companies, Inc.

Sodium Phenylbutyrate Drugs Market: Research Scope

Sodium Phenylbutyrate Drugs Market, by Route of Administration

  • Oral
  • Nasogastric Intubation

Sodium Phenylbutyrate Drugs Market, by Distribution Channel

  • Hospital Pharmacies
  • Online
  • Retail Pharmacies

Interested in this report?
Get a FREE Brochure now!

Request Brochure

*Get Brochure (PDF) sent to your email within minutes


Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.


Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved